Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.
Also called NCT01763918
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 331 participants
- Sponsor
- Registry
-
NCT01763918 -
2012-001365-32
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, France, Germany, Hong Kong SAR China, Netherlands, New Zealand, Norway, South Africa, Spain, Sweden, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01763918. Randomized; quadruple masking; primary purpose treatment. Start 2013-02-07 (actual); primary completion 2013-11-27 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
- Acronym
- RUTHERFORD-2
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01763918- Content hash
2c5ee60e4fdffd4c03b4960e22ab67ec74d8c8cc3986064776323a4aed367e97